In a report of 3 patients treated with pegvisomant, linear growth was interrupted after 6 months of treatment, and improvement in diaphoresis and facial features of acromegaly was observed, along with normalization of IGF-1 levels in 2 of them, while the other one showed an increase in tumor size (9). The gene discussed is IGF1; the disease is neoplasm.